Franklyn JA. What is the role of radioiodine uptake measurement and thyroid scintigraphy in the diagnosis and management of hyperthyroidism[J]. Clin Endocrinol, 2010, 70(1): 11-12.
[2]
中华医学会临床技术操作规范核医学分册[M]. 北京: 人民军医出版社, 2004: 79-80.
[3]
匡安仁, 李林. 核医学[M]. 北京: 高等教育出版社, 2008: 88-89.
[4]
Merrill S, Horowitz J, Traino AC, et al. Accuracy and optimal timing of activity measurements in estimating the absorbed dose of radioiodine in the treatment of Graves’ disease[J]. Phys Med Biol, 2011, 56(3): 557-571.
[5]
Ross DS. Radioiodine therapy for hyperthyroidism[J]. N Engl J Med, 2011, 364(6): 542-550.
[6]
AlSharif AA, Abujbara MA, Chiacchio S, et al. Contribution of radioiodine uptake measurement and thyroid scintigraphy to the differential diagnosis of thyrotoxicosis[J]. Hell J Nucl Med, 2010, 13(2): 132-137.
[7]
Traino AC, Grosso M, Mariani G. Possibility of limiting the un-justified irradiation in 131I therapy of Graves’ disease: a thyroid mass-reduction based method for the optimum activity calculation[J]. Phys Medica, 2010, 26(2): 71-79.
[8]
Van Isselt JW, Broekhuizen-de Gast HS. The radioiodine turnover rate as a determinant of radioiodine treatment outcome in Graves’ disease[J]. Hell J Nucl Med, 2010, 13(1): 2-5.
[9]
Salvatori M, Luster M. Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma[J]. Euro J Nucl Med Mol Imaging, 2010, 37(4): 821-828.
[10]
Kobe C, Eschner W, Wild M, et al. Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I [J]. Nucl Med Commun, 2010, 31(3): 201-205.
